38 results about "Complement Inhibitors" patented technology

The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

The present invention relates to a method for preventing or treating sepsis by co-administering to a patient a sepsis preventing or treating amount of one or more complement inhibitors and a sepsis preventing or treating amount of one or more CD14 pathway inhibitors. The complement inhibitor is preferably an antibody that binds to and inhibits a complement protein such as C5a, and the CD14 pathway inhibitor is preferably an antibody that binds to and inhibits components of the CD14 pathway such as CD14 and LPS.

The method of the invention relates to a modified OmCI polypeptide or a polynucleotide encoding a modified OmCI polypeptide which lacks LK / E binding activity and the use of such polypeptides and polynucleotides for the treatment of a disease or condition mediated by complement.

The invention discloses a target fusion protein with the anti-inflammatory action, in particular an anti-P lectin single chain antibody target complement inhibitor ScFv-Crry and application thereof. The invention aims to provide the anti-P lectin single chain antibody target complement inhibitor ScFv-Crry with the specific targeting property and application of the ScFv-Crry to the preparation of medicines for treating organism inflammatory reactions. The anti-P lectin single chain antibody target complement inhibitor ScFv-Crry is the fusion protein which is obtained through the connection between an amino end connected with an anti-P lectin single chain antibody ScFv and a complement inhibitor Crry(1-319aa). Experiments show that the ScFv-Crry can remarkably improve the efficiency of the cell cracking mediated by an inhibiting complement, be highly aggregated at an immunity damaged position, and obviously inhibit the generation and development of inflammation. Therefore, the ScFv-Crrycan be prepared into target P lectin complement inhibitor new genetic engineering target protein medicines aiming at treating inflammatory reactions. The ScFv-Crry has important contributions to the field of pharmacy and bright application prospect.

The invention belongs to the field of traditional Chinese medicine pharmacy, and relates to a sterol lactam compound and its application in preparing anti-complement drugs. The present invention separates and obtains the sterol lactam compound piprolactam from the fruiting body of puffball, and the compound is ergosterol of the B-ring lactam. After the anti-complement activity evaluation test, the results confirm that the sterol lactam compound piprolactam Amide has a strong inhibitory effect on the activation of the classical pathway and the alternative pathway of the complement system, with a CH50 value of 0.032±0.007mg / ml and an AP50 value of 0.067±0.009mg / ml. The compounds are useful in the preparation of complement inhibitors.